judonebolayb1394.blogspot.com
The biopharmaceutical industry has argued that the five years of protectionb offered by Waxmanin H.R. 1427 woulr stifle innovation. But the in a repor earlier this month said the 12 to 14 yearsx that the industry has said publiclgy that it wants also would hurt innovation and delay access tocheaper drugs. Eshoo’s H.R. 1548 calls for a 12-yeard period of data exclusivity, basically protecting the patents coverinhg innovativebiotech therapies.
In a letter to Nancy-Ann DeParle, Obama’s health-care reform director, and budget director Petetr Orszagsaid “the seven-year policy in the FY 2010 Budgegt is a generous compromise between what the FTC research has concludes and what the pharmaceutical industry has , however, said it is “extremely concerned” that the seven-year plan is “q risky shortcut to biosimilars.
” “We believde this abbreviated period will undermine the incentivesd necessary for continued biotech research into breakthrough medicines and cures for diseases such as cancer, multiple Alzheimer’s and HIV/AIDS as well as unmet medical BIO President and CEO Jim Greenwood said in a Besides patent exclusivity, the industry has arguex that drugs developed by biotech companiew can’t be copied like pharmaceutical drugs because they are complec to make and the finished productsw can differ.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment